SCHEMBL3193066

SCHEMBL3193066

O=Cc1nc(-c2ccccc2Cl)cs1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 1/20 0.53
▸ GSTO1 P78417 1/20 0.51
▸ ATP4A P20648 2/20 0.50
▸ ATP4B P51164 2/20 0.50
▸ KDM4E B2RXH2 2/20 0.49
▸ NPC1 O15118 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ KDM1A O60341 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.45
▸ HPGD P15428 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ L3MBTL1 Q9Y468 3/20 0.45
▸ LMNA P02545 4/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ MAPT P10636 1/20 0.43
▸ DHODH Q02127 3/20 0.43
▸ CYP1A1 P04798 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP1B1 Q16678 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13510366 0.80 HTR2B (0.55) CYP19A1GSTO1ATP4AATP4BNPC1
SCHEMBL27570571 0.80 AR (0.47) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL24107619 0.76 GSTO1 (0.61) CYP19A1GSTO1ATP4AATP4BKDM4E
SCHEMBL13284002 0.76 CYP19A1 (0.56) CYP19A1GSTO1ATP4AATP4BKDM4E
SCHEMBL3772673 0.75 CYP19A1 (0.58) CYP19A1GSTO1ATP4AATP4BKDM4E
SCHEMBL30123146 0.75 HSD17B10 (0.62) CYP19A1GSTO1ATP4AATP4BKDM4E
SCHEMBL38240 0.75 HSD17B10 (0.62) CYP19A1GSTO1ATP4AATP4BKDM4E
SCHEMBL30378574 0.75 CYP19A1 (0.58) CYP19A1GSTO1ATP4AATP4BKDM4E
SCHEMBL2224538 0.75 ALDH1A1 (0.55) CYP19A1GSTO1KDM4ENPC1RAB9A
SCHEMBL13510369 0.74 CYP19A1 (0.41) CYP19A1GSTO1ATP4AATP4BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394841-B2 Compounds and methods for modulating G protein-coupled receptors IRM LLC (BM) 2013-03-12 — — US disclosed
US-8394841-B2 Compounds and methods for modulating G protein-coupled receptors IRM LLC (BM) 2013-03-12 — — US disclosed
US-8394841-B2 Compounds and methods for modulating G protein-coupled receptors IRM LLC (BM) 2013-03-12 — — US disclosed
US-20100035944-A1 COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2010-02-11 — — US disclosed
US-20100035944-A1 COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2010-02-11 — — US disclosed
US-20100035944-A1 COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2010-02-11 — — US disclosed
CN-101646660-A Compounds and methods for modulating G protein-coupled receptors IRM LLC VG 2010-02-10 — — CN disclosed
EP-2125758-A1 COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2009-12-02 — — EP disclosed
WO-2008103501-A1 COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2008-08-28 — — WO disclosed
WO-2008103501-A1 COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2008-08-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035944-A1 COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS GRK2, GRK3, GRK5 CYP19A1 2227/4885GSTO1 1453/4885ATP4A 2974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback